title: Impact of genetic polymorphisms of cytochrome P450 2 C (CYP2C) enzymes on the drug metabolism and design of antidiabetics.
abstract: CYP2C enzymes are responsible for the oxidative metabolism of a diverse number of drugs for the treatment of type 2 diabetes mellitus, a severe metabolic disorder with high prevalence. Various clinical studies found the close association between CYP2C polymorphisms and altered pharmacokinetics, toxicological profiles, and drug-drug interactions of antidiabetic drugs. In this brief review, we discussed the impact of CYP2C polymorphisms on the metabolic fate of small-molecule antidiabetics including sulfonylureas, meglitinides, thiazolidinediones, gliptins, and gliflozins, with the key drug-protein molecular interactions highlighted.
authors.affiliation: Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., Groton, CT, United States. hao.sun@pfizer.com
authors.forename: Hao
authors.initials: H
authors.lastname: Sun
authors.forename: Dennis O
authors.initials: DO
authors.lastname: Scott
mesh_terms: D000818:Animals; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics* / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D015195:Drug Design; D006801:Humans; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000378:metabolism* / Q000493:pharmacokinetics / Q000627:therapeutic use; D011110:Polymorphism, Genetic
chemical_list: D007004:Hypoglycemic Agents; C400322:cytochrome P-450 CYP2C subfamily; D003577:Cytochrome P-450 Enzyme System